Biogen appoint new Head of Global Therapeutic Operations
pharmafile | June 27, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Biogen, Jean-Paul Kress
Biogen announced that Jean-Paul Kress has been appointed to the position of Executive Vice President and President, International, and Head of Global Therapeutic Operations.
Kress will be particularly responsible for worldwide commercial operations outside of the US and will perform an auxiliary role overseeing the Rare and Speciality Disease Asset teams.
He will join Biogen having had a broad experience of the pharmaceutical industry, having worked at a number of big pharma companies. Particularly, he worked at Eli Lilly early in his career before moving on to an eight-year stint at Abbott. He then moved onto become Vice President and General Manager of Gilead, France. Notably, he held the role of President and CEO of Sanofi Pasteur MSD for four years, at the vaccine business formed as part of the collaboration between Sanofi and MSD.
“Having watched Biogen excel in the neurology space, it is truly exciting to be joining such an admired and respected industry leader,” said Kress. “Biogen’s clear and unwavering commitment to neuroscience and to critically underserved patient populations is unique and extremely inspiring.”
“Jean-Paul brings deep expertise and decades of industry experience to Biogen at an important time for the company,” said Biogen CEO Michael Vounatsos. “As we seek to optimize our commercial function in support of our investigational compounds and build upon the leadership position of our current therapies, I believe that Jean-Paul’s strategic vision and sharp customer focus will help ensure that patients around the world gain access to transformative therapies.”
Related Content
Biogen’s high-dose Spinraza regimen receives European Commission approval for spinal muscular atrophy
Biogen’s Spinraza (nusinersen) has received approval from the European Commission (EC) as a new high-dose …
Biogen and Stoke report positive results for Dravet syndrome drug
Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which …
Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China
Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a …
